I. Kim, J. Shin, and I. Kim, Histone Deacetylase Inhibitor-Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53, Clinical Cancer Research, vol.12, issue.3, pp.940-949, 2006.
DOI : 10.1158/1078-0432.CCR-05-1230

A. Mai, S. Massa, R. Pezzi, D. Rotili, P. Loidl et al., Discovery of (Aryloxopropenyl)pyrrolyl Hydroxyamides as Selective Inhibitors of Class IIa Histone Deacetylase Homologue HD1-A, Journal of Medicinal Chemistry, vol.46, issue.23, pp.4826-4829, 2003.
DOI : 10.1021/jm034167p

A. Mai, S. Massa, and R. Pezzi, Class II (IIa)-Selective Histone Deacetylase Inhibitors. 1. Synthesis and Biological Evaluation of Novel (Aryloxopropenyl)pyrrolyl Hydroxyamides, Journal of Medicinal Chemistry, vol.48, issue.9
DOI : 10.1021/jm049002a

P. Jones, S. Altamura, and D. Francesco, Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases, Bioorganic & Medicinal Chemistry Letters, vol.18, issue.6, pp.1814-1819, 2008.
DOI : 10.1016/j.bmcl.2008.02.025

A. Lahm, C. Paolini, and M. Pallaoro, Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases, Proceedings of the National Academy of Sciences, vol.104, issue.44, pp.17335-17340, 2007.
DOI : 10.1073/pnas.0706487104

M. Dokmanovic, G. Perez, and W. Xu, Histone deacetylase inhibitors selectively suppress expression of HDAC7, Molecular Cancer Therapeutics, vol.6, issue.9, pp.2525-2534, 2007.
DOI : 10.1158/1535-7163.MCT-07-0251

H. Kawai, H. Li, A. S. Jiang, S. Avraham, and H. , Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor ?, International Journal of Cancer, vol.60, issue.33, pp.353-358, 2003.
DOI : 10.1002/ijc.11403

R. Varshochi, F. Halim, A. Sunters, and . Ici182, ICI182,780 Induces p21Waf1 Gene Transcription through Releasing Histone Deacetylase 1 and Estrogen Receptor ?? from Sp1 Sites to Induce Cell Cycle Arrest in MCF-7 Breast Cancer Cell Line, Journal of Biological Chemistry, vol.280, issue.5, pp.3185-3196, 2005.
DOI : 10.1074/jbc.M408063200

C. Krusche, P. Kersting, and C. , Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis, Breast Cancer Research and Treatment, vol.107, issue.1, pp.15-23, 2005.
DOI : 10.1007/s10549-004-1668-2

S. Saji, M. Kawakami, and S. Hayashi, Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer, Oncogene, vol.10, issue.28
DOI : 10.1038/sj.onc.1208646

Z. Zhang and H. Yamashita, HDAC6 Expression Is Correlated with Better Survival in Breast Cancer, Clinical Cancer Research, vol.10, issue.20, pp.6962-6968, 2004.
DOI : 10.1158/1078-0432.CCR-04-0455

M. Ocker and . Schneider-stock, Histone deacetylase inhibitors: Signalling towards p21cip1/waf1, The International Journal of Biochemistry & Cell Biology, vol.39, issue.7-8, pp.1367-1374, 2007.
DOI : 10.1016/j.biocel.2007.03.001

K. Glaser, J. Li, M. Staver, R. Wei, and D. Albert, Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA, Biochemical and Biophysical Research Communications, vol.310, issue.2, pp.529-536, 2003.
DOI : 10.1016/j.bbrc.2003.09.043

G. Lagger, . Carroll-'d, and M. Rembold, Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression, The EMBO Journal, vol.21, issue.11, pp.2672-2681, 2002.
DOI : 10.1093/emboj/21.11.2672

S. Senese, K. Zaragoza, and S. Minardi, Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation, Molecular and Cellular Biology, vol.27, issue.13, pp.4784-4795, 2007.
DOI : 10.1128/MCB.00494-07

S. Nakata, T. Yoshida, M. Horinaka, T. Shiraishi, M. Wakada et al., Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells, Oncogene, vol.23, issue.37, pp.6261-6271, 2004.
DOI : 10.1038/sj.onc.1207830

R. Rosato and S. Grant, Histone deacetylase inhibitors: insights into mechanisms of lethality, Expert Opinion on Therapeutic Targets, vol.63, issue.1, pp.809-824, 2005.
DOI : 10.1016/S0092-8674(03)00939-5

V. Chopin, C. Slomianny, H. Hondermarck, and L. Bourhis, Synergistic induction of apotosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors signaling and requires p21